Mr. President, I rise to call for a new effort to combat an often deadly form of cancer--by re-introducing the Lung Cancer Mortality Reduction Act. I am pleased to be joined by my cosponsors, Senator…
Mr. President, I rise to call for a new effort to combat an often deadly form of cancer--by re-introducing the Lung Cancer Mortality Reduction Act. I am pleased to be joined by my cosponsors, Senator Isakson and Senator Kerry on this very important bill.
This bill will renew and improve Federal government's efforts to combat lung cancer. It will: set a goal to reduce lung cancer mortality by 50 percent by 2020; establish a Lung Cancer Mortality Reduction Program, with comprehensive interagency coordination, to develop and implement a plan to meet this goal; improve disparity programs to ensure that the burdens of lung cancer on minority populations are addressed; create a computed tomography screening demonstration project based on recent science; and establish a Lung Cancer Advisory Board, which will provide an annual report to Congress on the progress of the Mortality Reduction Program.
We have made great strides against many types of cancer in the last several decades. However, these gains are uneven.
When the National Cancer Act was passed in 1971, lung cancer had a 5- year survival rate of only 12 percent. After decades of research efforts and scientific advances, this survival rate remains only 15 percent.
In contrast, the 5 year survival rates of breast, prostate, and colon cancer have risen to 89, 99 and 65 percent respectively.
Lung cancer is the leading cause of cancer death for both men and women, accounting for 28 percent of all cancer deaths.
Lung cancer causes more deaths annually than: colon cancer, breast cancer, prostate cancer, and pancreatic cancer combined.
A National Cancer Institute study in 2009 indicated that the value of life lost to lung cancer will exceed $433 billion annually by 2020.
A four percent annual decline in mortality would reduce this amount by more than half.
A lung cancer diagnosis can be devastating. The average life expectancy following a lung cancer diagnosis is only 9 months.
This is because far too many patients are not diagnosed with lung cancer until it has progressed to the later stages. Lung cancer can be hard to diagnose, and symptoms may at first appear to be other illnesses, such as bronchitis, chronic obstructive pulmonary disease, or asthma.
As a result, only 16 percent of lung cancer patients are diagnosed when their cancer is still localized, and is the most treatable.
When I introduced this legislation in 2009, lung cancer lacked early detection technology, to find the cancer when it was most treatable. Now, however, preliminary results show a screening method with a demonstrated reduction in mortality for lung cancer.
In 2010, the National Cancer Institute released initial results from the National Lung Screening Trial, a large-scale study of screening methods to detect lung cancers at earlier stages.
The National Lung Screening Trial found a 20 percent reduction in lung cancer mortality among participants screened with the computed tomography screening versus a traditional X-ray.
This is the first time that researchers have seen evidence of a significant reduction in lung cancer mortality with a screening test.
This is why this legislation also includes the creation of a computed tomography screening demonstration project, to assess public health needs of screening for lung cancer, and develop the most effective, safe, equitable, and efficient process to maximize the benefit of screening.
Efforts to fight lung cancer lag behind other cancers, in part, due to stigma from smoking. Make no mistake, tobacco use causes the majority of lung cancer cases.
Tobacco cessation is a critical component of reducing lung cancer mortality. Less smoking means less lung cancer. Period.
But tobacco use does not fully explain lung cancer. Approximately 20 percent of lung cancer patients never smoked.
Two-thirds of individuals diagnosed with lung cancer who have never smoked are women.
60 percent of lung cancer patients are former smokers who quit, often decades ago.
These patients may have been exposed to second hand smoke, or they may have been exposed to radon, asbestos, chromium, or other chemicals. There could be other causes and associations that have not yet been discovered, genetic predispositions or other environmental exposures.
The President's National Cancer Advisory Board Report of 2010 identified radon as the second leading cause of lung cancer after smoking and listed 15 other environmental contaminants strongly associated with lung cancer.
I believe that we have the expertise and technology to make serious progress against this deadly cancer, and to reach the goal of halving lung cancer mortality by 2020.
We need this legislation to ensure that our government's resources are focused on this mission in the most efficient way possible.
Agency efforts must be coordinated, and all sectors of the federal government that may have some ideas to lend should be participating. That is what the Lung Cancer Mortality Reduction Program will accomplish.
In this bill the Secretary of Health and Human Services is tasked to work
in consultation with Secretaries and Directors from the Department of Defense, Veterans Affairs, the National Institutes of Health, the Centers for Disease Control and Prevention, and Food and Drug Administration, the Centers for Medicare and Medicaid, and the National Center on Minority Health and Health Disparities.
This means that each agency with an expertise on lungs, imaging, and cancer will be included in this long overdue process.
We can do better for Americans diagnosed with lung cancer. I ask my colleagues to support this legislation.
Mr. President, I ask unanimous consent that the text of the bill be printed in the Record.